Magnolol prevents ovariectomy‑induced bone loss by suppressing osteoclastogenesis via inhibition of the nuclear factor‑κB and mitogen‑activated protein kinase pathways

Fei,Wen‑Yong; Huo,Qiang; Zhao,Pei‑Qing; Qin,Long‑Juan; Li,Tao

doi:10.3892/ijmm.2019.4099

Magnolol prevents ovariectomy‑induced bone loss by suppressing osteoclastogenesis via inhibition of the nuclear factor‑κB and mitogen‑activated protein kinase pathways

Authors:
- Wen‑Yong Fei
- Qiang Huo
- Pei‑Qing Zhao
- Long‑Juan Qin
- Tao Li
View Affiliations

Affiliations: Department of Orthopedics, Northern Jiangsu People's Hospital, Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu 225001, P.R. China, Center of Translational Medicine, Central Hospital of Zibo, Shandong University, Zibo, Shandong 255036, P.R. China, Orthopedic Basic and Translational Research Center, Jiangyin, Jiangsu 214400, P.R. China
Published online on: February 18, 2019 https://doi.org/10.3892/ijmm.2019.4099
Pages: 1669-1678
Copyright: © Fei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Magnolol is the active component of the traditional Chinese medicine Magnolia officinalis, and has antioxidant, anti‑inflammatory and anticancer activities, as well as an effect on bone metabolism in vitro. In the present study, it is reported that magnolol suppresses osteoclastogenesis in vivo and in vitro. Magnolol prevented ovariectomy‑induced bone loss and osteoclastogenesis in vivo, and decreased the serum levels of C‑terminal telopeptide of type 1 collagen, interleukin‑6, tumor necrosis factor (TNF)‑α and tartrate‑resistant acid phosphatase 5B. In vitro, magnolol inhibited the osteoclastogenesis induced by the receptor activator for nuclear factor‑κB ligand, and impaired the osteoclast function in bone marrow monocytes and RAW264.7 cells in a dose‑dependent manner. Furthermore, magnolol suppressed the expression levels of the osteoclastogenesis markers cathepsin K, calcitonin receptor, matrix metalloproteinase 9, TNF receptor‑associated factor 6 and tartrate‑resistant acid phosphatase by inhibiting the nuclear factor‑κB and mitogen‑activated protein kinase pathways. Therefore, magnolol is a promising agent for the treatment of osteoporosis and associated disorders.

View Figures

View References

1	Bateman ME, Strong AL, McLachlan JA, Burow ME and Bunnell BA: The effects of endocrine disruptors on adipogenesis and osteogenesis in mesenchymal stem cells: A review. Front Endocrinol (Lausanne). 7:1712016.
2	Noel SE, Mangano KM, Griffith JL, Wright NC, Dawson-Hughes B and Tucker KL: Prevalence of osteoporosis and low bone mass among Puerto Rican older adults. J Bone Miner Res. 33:396–403. 2018. View Article : Google Scholar :
3	Aldaghri NM, Aziz I, Yakout S, Aljohani NJ, Al-Saleh Y, Amer OE, Sheshah E, Younis GZ and Al-Badr FB: Inflammation as a contributing factor among postmenopausal Saudi women with osteoporosis. Medicine (Baltimore). 96:e57802017. View Article : Google Scholar
4	Paschalis EP, Gamsjaeger S, Hassler N, Fahrleitner-Pammer A, Dobnig H, Stepan JJ, Pavo I, Eriksen EF and Klaushofer K: Vitamin D and calcium supplementation for three years in postmenopausal osteoporosis significantly alters bone mineral and organic matrix quality. Bone. 95:41–46. 2017. View Article : Google Scholar
5	Gielen E, Bergmann P, Bruyère O, Cavalier E, Delanaye P, Goemaere S, Kaufman JM, Locquet M, Reginster JY, Rozenberg S, et al: Osteoporosis in frail patients: A consensus paper of the belgian bone club. Calcif Tissue Int. 101:111–131. 2017. View Article : Google Scholar : PubMed/NCBI
6	Ensrud KE and Crandall CJ: Osteoporosis Ann Intern Med. 167:ITC17–ITC32. 2017. View Article : Google Scholar
7	Office of the Surgeon General (US): Bone Health and Osteoporosis: A Report of the Surgeon General. Office of the Surgeon General; Rockville, MD: 2004
8	Peng C, Li Z and Hu Y: Prevalence of osteoporosis in China: A meta-analysis and systematic review. Bmc Public Health. 16:10392016. View Article : Google Scholar
9	Zhou Y, Guan X, Chen X, Yu M, Wang C, Chen X, Shi J, Liu T and Wang H: Angiotensin II/Angiotensin II receptor blockade affects osteoporosis via the AT1/AT2-mediated cAMP-dependent PKA pathway. Cells Tissues Organs. 204:25–37. 2017. View Article : Google Scholar : PubMed/NCBI
10	Xu L, Zhang L, Zhang H, Yang Z, Qi L, Wang Y and Ren S: The participation of fibroblast growth factor 23 (FGF23) in the progression of osteoporosis via JAK/STAT pathway. J Cell Biochem. 119:3819–3828. 2018. View Article : Google Scholar
11	Wang Y, van Assen AHG, Reis CR, Setroikromo R, van Merkerk R, Boersma YL, Cool RH and Quax WJ: Novel RANKL DE-loop mutants antagonize RANK-mediated osteoclastogenesis. FEBS J. 284:2501–2512. 2017. View Article : Google Scholar : PubMed/NCBI
12	Okabe I, Kikuchi T, Mogi M, Takeda H, Aino M, Kamiya Y, Fujimura T, Goto H, Okada K, Hasegawa Y, et al: IL-15 and RANKL play a synergistically important role in osteoclastogenesis. J Cell Biochem. 118:739–747. 2017. View Article : Google Scholar
13	Yang X, Gao W, Wang B, Wang X, Guo H, Xiao Y, Kong L and Hao D: Picroside II Inhibits RANKL-mediated Osteoclastogenesis by attenuating the NF-κB and MAPKs signaling pathway in vitro and prevents bone loss in lipopolysaccharide treatment mice. J Cell Biochem. 118:4479–4486. 2017. View Article : Google Scholar : PubMed/NCBI
14	Ueno M, Cho K, Isaka S, Nishiguchi T, Yamaguchi K, Kim D and Oda T: Inhibitory effect of sulphated polysaccharide porphyran (isolated from Porphyra yezoensis) on RANKL-induced differentiation of RAW264.7 cells into osteoclasts. Phytother Res. 32:452–458. 2018. View Article : Google Scholar
15	Chen X, Zhi X, Pan P, Cui J, Cao L, Weng W, Zhou Q, Wang L, Zhai X, Zhao Q, et al: Matrine prevents bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclastogenesis. FASEB J. 31:4855–4865. 2017. View Article : Google Scholar : PubMed/NCBI
16	Dong J, Ding H, Liu Y, Yang Q, Xu N, Yang Y and Ai X: Magnolol protects channel catfish from Aeromonas hydrophila infection via inhibiting the expression of aerolysin. Vet Microbiol. 211:119–123. 2017. View Article : Google Scholar : PubMed/NCBI
17	Zhang Li M, Wang F, Wu X, Zhang X, Zhang B, Wu N, Wang W, Weng Z, Liu HS, et al: Magnolol inhibits growth of gallbladder cancer cells through the p53 pathway. Cancer Sci. 106:1341–1350. 2015. View Article : Google Scholar : PubMed/NCBI
18	Wei W, Dejie L, Xiaojing S, Tiancheng W, Yongguo C, Zhengtao Y and Naisheng Z: Magnolol inhibits the inflammatory response in mouse mammary epithelial cells and a mouse mastitis model. FEBS J. 38:16–26. 2015.
19	Yang B, Xu Y, Yu S, Huang Y, Lin L and Liang X: Anti-angiogenic and anti-inflammatory effect of Magnolol in the oxygen-induced retinopathy model. Inflamm Res. 65:81–93. 2016. View Article : Google Scholar
20	Park KR, Kim JY, Kim EC, Yun HM and Hong JT: RANKL-induced osteoclastogenesis is suppressed by 4-O-methylhonokiol in bone marrow-derived macrophages. Arch Pharm Res. 40:933–942. 2017. View Article : Google Scholar : PubMed/NCBI
21	Jeong JH, Jin ES, Kim JY, Lee B, Min J, Jeon SR, Lee M and Choi KH: The effect of biocomposite screws on bone regeneration in a rat osteoporosis model. World Neurosurg. 106:964–972. 2017. View Article : Google Scholar : PubMed/NCBI
22	Chen P, Li Z and Hu Y: Prevalence of osteoporosis in China: A meta-analysis and systematic review. Bmc Public Health. 16:10392016. View Article : Google Scholar : PubMed/NCBI
23	McClung M, Baron R and Bouxsein M: An update on osteoporosis pathogenesis, diagnosis, and treatment. Bone. 98:372017. View Article : Google Scholar : PubMed/NCBI
24	Chen X, Wang Z, Duan N, Zhu G, Schwarz EM and Xie C: Osteoblast-osteoclast interactions. Connect Tissue Res. 59:99–107. 2018. View Article : Google Scholar
25	Stoecker WV, Carson A, Nguyen VH, Willis AB, Cole JG and Rader RK: Addressing the crisis in the treatment of osteoporosis: Better paths forward. J Bone Miner Res. 32:1386–1387. 2017. View Article : Google Scholar : PubMed/NCBI
26	Liu Q, Wang T, Zhou L, Song F, Qin A, Feng HT, Lin XX, Lin Z, Yuan JB, Tickner J, et al: Nitidine chloride prevents OVX-induced bone loss via suppressing NFATc1-mediated osteoclast differentiation. Sci Rep. 6:366622016. View Article : Google Scholar : PubMed/NCBI
27	Kwak EJ, Lee YS and Choi EM: Effect of magnolol on the function of osteoblastic MC3T3-E1 cells. Mediators Inflamm. 2012.829650:2012.
28	Park JW, Yoon HJ, Kang WY, Cho S, Seong SJ, Lee HW, Yoon YR and Kim HJ: G protein-coupled receptor 84 controls osteoclastogenesis through inhibition of NF-κB and MAPK signaling pathways. J Cell Physiol. 233:1481–1489. 2018. View Article : Google Scholar
29	Chen X, Zhi X, Cao L, Weng W, Pan P, Hu H, Liu C, Zhao Q, Zhou Q, Cui J and Su J: Matrine derivate MASM uncovers a novel function for ribosomal protein S5 in osteoclastogenesis and postmenopausal osteoporosis. Cell Death Dis. 8:e30372017. View Article : Google Scholar : PubMed/NCBI
30	Guan H, Zhao L, Cao H, Chen A and Xiao J: Epoxyeicosanoids suppress osteoclastogenesis and prevent ovariectomy-induced bone loss. FASEB J. 29:1092–1101. 2015. View Article : Google Scholar
31	Lu SH, Huang RY and Chou TC: Magnolol ameliorates ligature-induced periodontitis in rats and osteoclastogenesis: In vivo and in vitro study. Evid Based Complement Alternat Med. 2013.634095:2013.
32	Kanzaki H, Shinohara F, Itohiya K, Yamaguchi Y, Katsumata Y, Matsuzawa M, Fukaya S, Miyamoto Y, Wada S and Nakamura Y: RANKL induces Bach1 nuclear import and attenuates Nrf2-mediated antioxidant enzymes, thereby augmenting intracellular reactive oxygen species signaling and osteoclastogenesis in mice. FASEB J. 31:781–792. 2017. View Article : Google Scholar